CardioVascular BioTherapeutics Co-Founder to Present Seminar on New Treatment for Heart Disease; Renowned Cardiac & Thoracic Surgeon Dr. Thomas Stegmann to Introduce Novel Protein Drug Candidate.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that its Chief Clinical Officer, Dr. Thomas J. Stegmann, will present the keynote address at a free educational seminar presented by the Regenerative Medicine Organization, a Las Vegas based non-profit organization. Dr. Stegmann will discuss Cardio Vascu-Grow(TM), a drug candidate in U.S. Food and Drug Administration authorized clinical trials, that represents a potential new medical breakthrough in the treatment of heart disease.

Cardio Vascu-Grow(TM) is a protein that stimulates the growth and production of new blood vessels, a process called angiogenesis. CVBT recently announced completion of patient admission and administration of the drug in a Phase I clinical trial of Cardio Vascu-Grow(TM) in no-option heart patients. These are coronary heart patients who are not eligible for traditional interventional therapies such as stent or bypass procedures.

"We are excited to have developed a new way of addressing cardiovascular disease, which is the biggest health threat facing Americans today, killing nearly 2,500 each day," said Dr. Stegmann. "Cardio Vascu-Grow(TM) represents a potential breakthrough treatment and offers a chance to drastically change the effect that heart disease has on our society. Attendees will come away with an understanding of this great opportunity in the treatment of cardiovascular disease."

"Regenerative treatments such as Cardio Vascu-Grow(TM), which enhance the body's natural ability to regenerate tissues and organs, have the potential to radically reduce mortality and increase the quality of life of patients with cardiovascular diseases," said John Laub, Executive Director of Regenerative Medicine Organization. "Dr. Stegmann is a leading visionary in this field, and offers valuable insight into this new therapy for addressing cardiovascular disease."

The seminar is scheduled from six to seven p.m. on Wednesday, July 12, 2006, at the Four Seasons Hotel, 3960 S. Las Vegas Boulevard. There is no cost to attend the seminar and each registered attendee will receive a complimentary copy of Dr. Stegmann's book "New Vessels for the Heart."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in the area of coronary artery disease in no-option heart patients, and one in the area of impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the U.S.A. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked arteries has also been initiated.

Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.